INDIVIDUAL ARTICLE: Clinical and Real-World Implications of IL-17 Receptor Blockade in Plaque Psoriasis and Psoriatic Arthritis With Brodalumab

Brodalumab is a fully human monoclonal antibody targeting interleukin-17 receptor A (IL-17RA), providing a mechanistically distinct approach to inhibiting IL-17–mediated inflammation in plaque psoriasis and psoriatic arthritis (approved in Japan). Across pivotal randomized trials and extensive real-world studies, brodalumab demonstrates a rapid onset of action, high rates of complete skin clearance, durable efficacy, and consistent effectiveness across diverse patient subgroups, while randomized and real-world data also support meaningful improvements in joint outcomes among patients with concomitant psoriatic arthritis. This review synthesizes clinical trial and real-world evidence to contextualize the efficacy, safety, and clinical positioning of IL-17RA blockade with brodalumab across the spectrum of psoriatic disease.